Can we have some chips?

3:00 - RA is associated with elevated cardiac risk, but we’re still not great at predicting it. Josh Baker with abstract 1724 on a novel cardiovascular risk calculator in RA.

3:00 - How do you manage JAKI’s/IL17i’s for patients getting COVID19 boosters? Hold? Continue? Maybe get some clarity on this from COVER study of holding vs continuing JAKI/IL17i in pts getting COVID19 booster. @Mike George

3:00 - Adding to our information RE: treatment of RA-ILD – Josh Baker and Mike George on abstract 1713, comparing non-TNFI biologic and tsDMARDs in RA-ILD using VA data.

Is there an #ACR24 award for best presentation name? My nominee: “Z’s and knees”: association of PRO’s and sleep measures with pain among US veterans with knee OA. Alexis Ogdie, Josh Baker, and Carla Scanzello authors.

Tom Riley, Mike George, Josh Baker on relationship of weight loss, disease activity, and PRO’s in patients with MSK/autoimmune diseases on weight loss tx.

1:00 today is busy for Penn vasculitis!
- Rennie Rhee and Peter Merkel with abstract 0823: RCT of abatacept for treatment of relapsing non-severe GCA
- Peter Merkel on MANDARA trial of efficacy of eo-targeted tx on specific eGPA manifestations

Josh Baker presenting abstract 0803, looking at serum adipokines and ILD in prospective RA cohort. Metabolomics in RA

Penn Rheum fellow, Dr. Thomas Riley, presenting his work with Dr. Joshua Baker looking at genetic variation in CRP and its impact on disease activity assessment in VARA. Implications for how we monitor disease!

Upa with 26 week GC taper superior to placebo with 52 week GC taper in patients with new onset or relapsing GCA. Similar AE profile to placebo.

This is great! Done!